Introduction
============

KC is characterized by corneal thinning and ectasia, progressive myopia, and irregular astigmatism \[[@r1],[@r2]\], which affects both genders and all ethnicities \[[@r3]\]. KC usually begins in the late teens or early 20s and progresses until the fourth decade of life \[[@r4]\]. As the most common ectatic disorder, the prevalence of KC has been reported to vary from 8.8 to 54.4 per 100,000 individuals in different studies internationally \[[@r2]\], depending on the diagnostic criteria of KC, population characteristics, and structure \[[@r3]\]. Additionally, because of the limitation of medical treatments, up to 21% of patients with KC worldwide have an indication for corneal transplantation \[[@r1],[@r4],[@r5]\].

Despite extensive studies, the pathophysiology of KC remains unknown and complex. Multiple environmental and genetic factors are thought to be involved in the development of KC. As for its genetic etiology, KC is considered to be compatible with an autosomal inheritance pattern based on familial occurrence, with a higher concordance rate in monozygotic twins compared with dizygotic twins \[[@r6]\] and a 15--67 times higher prevalence in first-degree relatives than in the general population \[[@r7]\]. To date, multiple genes have been reported to be related to KC \[[@r8]-[@r10]\], including but not limited to lysyl oxidase (*LOX*; gene ID:4015, OMIM [153455](http://www.ncbi.nlm.nih.gov/omim/?term=153455)) \[[@r11]\], interleukin-1 (*IL1;* gene ID:3552, OMIM [147760](http://www.ncbi.nlm.nih.gov/omim/?term=147760)) \[[@r12]\], visual system homeo box 1 (*VSX1;* gene ID:30813, OMIM [605020](http://www.ncbi.nlm.nih.gov/omim/?term=605020)) \[[@r13]\], microRNA 184 (*mir184;* gene ID:406960, OMIM [613146](http://www.ncbi.nlm.nih.gov/omim/?term=613146)) \[[@r14]\], and transforming growth factor beta induced (*TGFBI;* gene ID:7045, OMIM [601692](http://www.ncbi.nlm.nih.gov/omim/?term=601692)) \[[@r15]\].

Although the physiologic role of the ZNF469 (gene ID:84627, OMIM [612078](http://www.ncbi.nlm.nih.gov/omim/?term=612078)) gene is not yet well-established, some evidence suggests that *ZNF469* (located on 16q24) may also contribute to the development of KC. Abu et al. reported that *ZNF469* shares 30% homology with the helical parts of three types of collagen (COL1A1, COL1A2, and COL4A1), which suggests that *ZNF469* may participate in collagen homeostasis in the human cornea \[[@r16]\]. Additionally, the ZNF469 protein may also function as a transcription factor or extranuclear regulator factor in the human cornea \[[@r17]\]. Several genetic analysis studies have been conducted to further ascertain the involvement of *ZNF469* in KC. Lu et al. reported that mutations in *ZNF469* could confer increased risk of KC \[[@r18]-[@r20]\], while recent sequencing analysis of *ZNF469* in patients with KC and high myopia showed no significant variants \[[@r4]\]. Thus, the involvement of *ZNF469* in KC remains contentious at present, prompting us to conduct the additional genetic studies described here.

*ZNF469* has not been thoroughly studied in Chinese patients with KC. In addition, it is unknown whether pathogenic variants identified in largely Caucasian populations are relevant to Asians, in whom the prevalence of KC is much higher and the age of onset of KC is much younger \[[@r1]\]. Therefore, we performed this analysis of the mutations in *ZNF469*, aiming to identify novel variants that may indicate the potential involvement of *ZNF469* in Chinese patients affected by KC.

Methods
=======

This study adhered to the tenets of the Declaration of Helsinki and was approved by the ethics committee of the 2nd Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, China. This study adhered to the Association for Research in Vision and Ophthalmology (ARVO) statement on human subjects. Written informed consent was obtained from every participant.

Subject identification
----------------------

Fifty-three patients with primary KC, 30 patients with HM (defined by a spherical equivalent (SE) of more than −6.00 diopters (D)), and 100 unrelated population-matched healthy controls without any ocular or systemic disorders, all of Han Chinese ethnicity, were recruited from the Eye Center of the 2nd Affiliated Hospital, Medical College of Zhejiang University, Hangzhou, China in 2015. The KC patients were aged from 11 to 43 years, including 31 males and 22 females. The first clinical diagnosis of KC patients was made at ages ranging from 9 to 36 years. The HM controls were aged from 19 to 35 years, including 17 males and 13 females. The healthy controls were aged from 16 to 45 years, including 49 males and 51 females. Only 53 patients with KC were willing to enroll in this study, which to the best of our knowledge was an apparently random sub-set of the total eligible population. The patients with HM were randomly selected with the random data table sampling method. Controls were recruited from healthy people who had undergone routine health examinations at this hospital. In addition, the absence of KC or HM was confirmed in all controls, who received ocular exams, including visual acuity measurement, slit-lamp examination, and corneal topography assessment. All patients with KC who were included had negative family histories for KC. The diagnosis of KC was made based on clinical manifestations: corneal stromal thinning, Vogt's striae, Fleischer ring, Munson's sign, conical protrusion of the cornea at the apex, an anterior corneal stromal scar using a slit-lamp microscope, and signs of videokeratography (localized increased surface power and/or inferior superior dioptric asymmetry \[Bausch & Lomb Surgical, Orbtek Inc., Salt Lake City, UT\]). According to the grading system used in the Collaborative Longitudinal Evaluation of Keratoconus Study, the severity of KC was divided into three categories using average keratometric readings: mild (\<45 D), moderate (45--52 D), and severe (\>52 D) \[[@r21]\]. The videokeratography pattern was classified into 11 categories \[[@r22]\]. Any patient with KC with coexisting allergy or atopy KC secondary to such causes as trauma, LASIK, or other refractive surgeries or who had Ehlers-Danlos syndrome, Down syndrome, osteogenesis imperfecta, or pellucid marginal degeneration was excluded from this research.

Mutation screening
------------------

We collected blood samples (5 ml) of the participates in Vacutainer tubes (Becton-Dickinson, Franklin Lakes, NJ) containing ethylene diamine tetra acetic acid (EDTA),preserved at -80 °C before being extracted genomic DNA with a Simgen DNA Blood Mini Kit (Simgen,Hangzhou,China) according to the manufacturer's instruction \[[@r23],[@r24]\] All patients with KC and HM and the healthy controls underwent mutation screening. For the patients with KC, the *ZNF469* gene was screened with next-generation sequencing technology, which is based on targeted sequence capturing technology with the SureSelect Target Enrichment Kit (Agilent Technologies, Santa Clara, CA) and the Illumina sequencing technology with the HiSeq Sequencer (Illumina , San Diego, CA). To avoid false-positive results and to ascertain the significance of the mutations in *ZNF469*, mutations (i) with a minor allele frequency (MAF) \<0.1% (according to data from the May 2012 release of the 1000 Genomes Project and the Single Nucleotide Polymorphism database) and (ii) absent from the results of the whole-exome sequencing (WES) data acquired from 220 Han Chinese individuals without ocular abnormalities (from a commercial database provided by the [Genesky Bio-Tech](http://biotech.geneskies.com/en/) company) were subsequently confirmed using Sanger sequencing technology. To further test whether the mutations in *ZNF469* identified in patients with KC with these two steps were potentially pathogenic mutations and could not be carried by healthy people, we screened these mutations in the patients with HM and the healthy controls with Sanger sequencing.

All coding regions (exons, intron--exon junctions, and promoter regions) of the *ZNF469* gene were amplified with PCR using specific primer sequences. Three different PCR conditions were involved in this study. 1) Reaction condition for fragments of 1 and 6:the cycling program was 95 °C 2 min; 35 cycles x (96 °C10 s, 68 °C1 min); 4 °C for ever. 2) Reaction condition for fragments of 3 to 5:the cycling program was 95 °C 2 min; 11 cycles x (94 °C 20 s, 66 °C-0.5 °C /cycle 40 s, 72 °C 1min); 24 cycles x (94 °C 20 s, 60 °C 30 s, 72 °C 1min); 72 °C 2min; 4 °C forever 3 ). Reaction condition for fragments of 2 and 7:the cycling program was 95 °C 2 min; 11 cycles x (94 °C 20 s, 62 °C-0.5 °C /cycle 40 s, 72 °C 1 min); 24 cycles x (94 °C 20 s, 56 °C 30 s, 72 °C 1min); 72 °C 2 min; 4 °C forever. The PCR products were isolated with electrophoresis and sequenced using the BigDye Terminator v3.1 Cycle sequencing kit (Applied Biosystems, Foster City, CA) on an Applied Biosystems ABI 3730 Sequencer Analyzer. Finally, the sequencing results were analyzed using the PolyPhred version and compared with the sequences in the [NCBI GenBank](https://www.ncbi.nlm.nih.gov/genbank/) database.

To further ensure the significance of the identified mutations in *ZNF469*, other potentially pathogenic genes related to KC were similarly assessed in the patients with KC with next-generation sequencing and follow-up Sanger sequencing. Details about these genes are shown in the supplemental materials (File S1).

Bioinformatics analysis
-----------------------

The Sorting Intolerant Form Tolerant ([SIFT](http://sift.jcvi.org/)) programs were used to predict the effect of amino acid substitution on the ZNF469 protein. Based on the theory of evolutionary conservation, the amino acid substitution is considered damaging if the SIFT score is ≤0.05; otherwise, the substitution is tolerated.

Statistical analysis
--------------------

All statistical analyses were conducted using SPSS software (Version 19.0, SPSS, Chicago, IL). Continuous numeric variables were presented as the mean ± standard deviation (SD). And no other statistical test was used in this study. Only descriptive statistics were used in this study, which were not related to the significance level.

Results
=======

The entire coding region, intron--exon junctions, and promoter regions of *ZNF469* were analyzed for mutations in 53 patients with sporadic KC. According to the next-generation sequencing results, 16 sequence variants in *ZNF469* were identified in this Chinese KC cohort, which are summarized in [Table 1](#t1){ref-type="table"}. All sequence variants were nonsynonymous single-nucleotide variants.

###### All *ZNF469* sequence variants identified in KC patients.

  Nucleotide change   Amino acid change   SNP ID        Frequency (1KG Project)   Position     Gene region   Mutation effect   SIFT score
  ------------------- ------------------- ------------- ------------------------- ------------ ------------- ----------------- ------------
  c.1370C\>A          p.A457D                                                     88,495,248   Exon          nonsynonymou      0.02
  c.1471G\>A          p.A491T             rs117555121   0.00998403                88,495,349   Exon          nonsynonymou      0.01
  c.2059G\>A          p.E687K                                                     88,495,937   Exon          nonsynonymou      0.02
  c.2137C\>A          p.P713T                                                     88,496,015   Exon          nonsynonymou      0.02
  c.2653C\>G          p.L885V             rs139653501   0.00459265                88,496,531   Exon          nonsynonymou      0
  c.3466G\>A          p.A1156T                                                    88,497,428   Exon          nonsynonymou      0
  c.3749C\>T          p.P1250L                                                    88,497,711   Exon          nonsynonymou      0
  c.4300G\>A          p.D1434N                          0.000199681               88,498,262   Exon          nonsynonymou      0
  c.4684G\>A          p.E1562K                                                    88,498,646   Exon          nonsynonymou      0
  c.7262G\>A          p.R2421H                          0.00119808                88,501,224   Exon          nonsynonymou      0
  c.10048G\>C         p.G3350R            rs192272765   0.000599042               88,504,010   Exon          nonsynonymou      0.05
  c.10633G\>A         p.G3545R            rs183149417   0.00179712                88,504,595   Exon          nonsynonymou      0.11
  c.946G\>A           p.E316K                           0.00599042                88,494,824   Exon          nonsynonymou      0
  c.2803G\>A          p.E935K             rs117995699   0.00638978                88,496,681   Exon          nonsynonymou      0
  c.10244G\>A         p.G3415E                          0.000998403               88,504,206   Exon          nonsynonymou      0.01
  c.2945G\>A          p.R982K                           0.000998403               88,496,823   Exon          nonsynonymou      0

After five known SNPs with MAF\>0.1% (c.1471G\>A, rs117555121; c.2653C\>G, rs139653501; c.10048G\>C, rs192272765; c.10633G\>A,rs183149417; and c.2803G\>A, rs117995699) and three single nucleotide variants (c.946G\>A, c.10244G\>A, and c.2945G\>A) that were also detected in the results of the WES data acquired from the 220 Han Chinese individuals without ocular abnormalities were excluded, eight novel mutations in *ZNF469* were selected for further characterization with Sanger sequencing technology to avoid false-positive results. The forward and reverse primers used in the direct PCR sequencing are summarized in [Table 2](#t2){ref-type="table"}; two mutations (c.2059G\>A and c.2137C\>A) with similar locations shared the same primer. With the use of Sanger sequencing, one mutation was identified as a false-positive result. The remaining seven mutations in *ZNF469* (c.2059G\>A, c.2137C\>A, c.3466G\>A, c.3749C\>T, c.4300G\>A, c.4684G\>A, and c.7262G\>A) were screened in 100 healthy controls, and none of the mutations were detected. We also screened the seven mutations in 30 patients with HM. Similarly, none of the mutations were detected.

###### Sequences of primers used in the study.

  Primer name   Fragment size (bp)   Primer sequence (5′ → 3′)
  ------------- -------------------- ---------------------------
  1F            423                  CCCTGCAGGTCCCCACCAACA
  1R                                 TGGGTTTGGGGCAGGCGGTACT
  2F            399                  AAGCAGCACAGCCAGTGACTT
  2R                                 CCCCGTGAGTGATTTGGTCT
  3F            383                  GTTCCTCGGACCCAAAGACCT
  3R                                 GCATCGGGGATACTTCCTCAA
  4F            362                  ACCCACTCACCCCCAGGAGAC
  4R                                 CCAGGAGCAGGCCACAGAACT
  5F            484                  CCTAGCTCCCTACCCCAGAGG
  5R                                 GAGCCCCAGGGTCTGTCATT
  6F            467                  GGGGCCGAGGCGAGAAGAGGA
  6R                                 GGGCGGCGGCTGCTCTGGTAT
  7F            251                  ATGAGTCACCTGTCCGAGGAT
  7R                                 CGATGTGCAGTGGATTCTCC

Other genes related to KC were also screened in the patients who carry the mutations in *ZNF469*. The patient with KC who carries mutation c.3466G\>A was detected as carrying one *DOCK9* mutation (c.1940C\>T). The SIFT score of the *DOCK9* mutation was 0, which is considered to be damaging.

Sequencing chromatograms of the seven novel mutations in *ZNF469* identified in this study are shown in [Figure 1](#f1){ref-type="fig"}, and all were located in the exonic region of *ZNF469*. None of the seven nonsynonymous mutations in *ZNF469* were classified as tolerated according to SIFT ([Table 1](#t1){ref-type="table"}).

![Sequence chromatogram of the seven novel mutations. **A**: c.2059G\>A (p.E687K). **B**: c.2137C\>A (p.P713T). **C**: c.3466G\>A(p.A1156T). **D**: c.3749C\>T (p.P1250L). **E**: c.4300G\>A(p.D1434N). **F**: c.4684G\>A (p.E1562K). **G**: c.7262G\>A(p.R2421H).](mv-v23-296-f1){#f1}

[Table 3](#t3){ref-type="table"} shows the characteristics of the seven patients with KC carrying the seven novel mutations in *ZNF469*. All patients with KC were diagnosed with bilateral KC, and 75% of the affected eyes were classified as having severe KC. The mean age of the seven patients was 19.2±4.2 years, and all were male. In terms of the videokeratography patterns, inferior steep (IS) was seen in 83.3% (ten) of the eyes with KC, irregular in 8.3% (one), and pellucid marginal degeneration (PMD) in 8.3% (one). Central corneal thickness (CCT) was examined in the patients with KC carrying the mutations in *ZNF469* with videokeratography during the initial visit, and the mean values were 396±85.9 μm.

###### *ZNF469* mutations and quantitative and qualitative video-keratographic parameters evaluated in KC patients.

  Subject   *ZNF469* mutations    Age at detection   Gender   Eye   Keratoplasty   Severity (OS/OD)   Video-keratography pattern
  --------- --------------------- ------------------ -------- ----- -------------- ------------------ ----------------------------
  1         c.3749C\>T:p.P1250L   23                 Male     OU    No             Severe/ Severe     IS/IS
  2         c.3466G\>A:p.A1156T   20                 Male     OU    No             Severe/Moderate    IS/IS
  3         c.2137C\>A:p.P713T    16                 Male     OU    No             Severe/ Severe     IS/Irregular
  4         c.2059G\>A:p.E687K    13                 Male     OU    No             Mild/Severe        IS/PMD
  5         c.4300G\>A:p.D1434N   24                 Male     OU    Yes            Severe/ Severe     IS/IS
  6         c.4684G\>A:p.E1562K   19                 Male     OU    No             Severe/Mild        IS/IS
  7         c.7262G\>A:p.R2421H   Na                 Male     OU    No             Na/Na              Na/Na

Discussion
==========

In this study, seven novel mutations (c.2059G\>A, c.2137C\>A, c.3466G\>A, c.3749C\>T, c.4300G\>A, c.4684G\>A, and c.7262G\>A) leading to the amino acid substitutions E687K, P713T, A1156T, P1250L, D1434N, E1562K, and R2421H, respectively, were identified in seven of the 53 patients with KC of Han Chinese ethnicity. The mutation in c.3466G\>A coexists with a potentially damaging *DOCK9* mutation in one patient with KC. All of the mutations were found in sporadic KC cases and were absent in the 30 patients with HM, the 100 healthy controls, and the results of the WES data acquired from the 220 Han Chinese individuals without ocular abnormalities. None of the seven mutations have been previously reported. To date, except the patient who carries mutations in *ZNF469* and *DOCK9*, the identification of the six potentially pathogenic novel mutations in *ZNF469* in 11.3% of the patients with KC in this study indicated that *ZNF469* might play an important role in corneal diseases in the Han Chinese population.

*ZNF469* is a two-exon gene encoding a 413 kDa protein consisting of 3,925 amino acid residues \[[@r25]\]. It is detected in a wide variety of tissues, including human corneas \[[@r16]\]. The five classical C2H2 zinc finger (ZNFs) domains in the C-terminus are the most important parts of the ZNF469 protein \[[@r16]\]. ZNFs can work as sequence-specific DNA-binding motifs to regulate specific transcription processes \[[@r16],[@r26]\]. In addition, the ZNF469 protein shares 30% homology with the helical parts of three types of collagen (COL1A1, COL1A2, and COL4A1), which are the major component of the human cornea \[[@r27]\]. Abu et al. argued that *ZNF469* may act as an extranuclear regulator factor for the synthesis and organization of human corneal collagen fibers \[[@r16]\], and functional mutations in *ZNF469* may affect the homogeneity and regular properties of corneal collagen fibrils.

Four of the seven novel mutations (E687K, P713T, A1156T, P1250L, and D1434N) lie in the compositionally biased (CB) regions of *ZNF469* \[[@r28]\], which are stretches that are primarily made up of a distinct subset of amino acid residues \[[@r28],[@r29]\]. CB regions are highly correlated to the structural roles of the proteins in cells and usually lead to protein disorders \[[@r28]\].

The possible involvement of *ZNF469* in corneal disease was first detected in Brittle cornea syndrome (BCS) type 1 \[[@r16],[@r25],[@r30]\]. BCS type 1 is an autosomal recessive disorder characterized by an extremely thin fragile cornea that tends to spontaneously rupture and shares the same corneal characteristics as KC \[[@r4]\]. In 2008, homozygous mutations in *ZNF469* were reported to be responsible for BCS type 1 for the first time \[[@r16]\]. A wide variety of mutations in *ZNF469* were then reported to confer an increased risk of isolated KC and BCS type 1 in patients of different ethnicities (23% of patients with KC from New Zealand, 50% KC patients of Maori or Polynesian descent, and 12.5% of patients with KC from three European KC cohorts \[[@r30]-[@r32]\]). However, there has been no clear consensus about whether *ZNF469* is a pathogenic gene for patients with KC of all ethnicities. For example, sequencing analyses of *ZNF469* in patients with KC and HM in Poland revealed no significant sequence variants compared with healthy individuals \[[@r4]\]. Similarly, Davidson et al. did not detect any non-synonymous *ZNF469* variants segregating in 11 families with KC from the United Kingdom, Dubai, and Saudi Arabia \[[@r30]\]. It seems that the role of *ZNF469* in corneal diseases might vary somewhat among different regions and races, and the present results indicated that the gene may have an important pathogenic role in the Han Chinese population.

Although all of the patients with KC carrying the mutations in *ZNF469* in this study were heterozygote, which indicates an autosomal dominant inheritance pattern, no parents or siblings of the identified patients with KC were tested. Without this information, it is difficult to determine the genetic pattern and significance of *ZNF469* in KC. The majority of recent pedigree studies based on a positive family history of KC suggested an autosomal dominant inheritance pattern \[[@r33]\]. However, some researchers hold the opinion that the inheritance pattern may be autosomal recessive or one that lies between autosomal recessive and dominant inheritance \[[@r34],[@r35]\]. The disagreements about the inheritance pattern may be due to diverse penetrance caused by different mutations in the same gene.

Corneal steepening, as assessed with the use of computer-assisted corneal tomography, is a common feature of KC, even at the early stage, although it is highly variable among patients with KC. The most frequent axial curvature pattern of the KC eyes in this study was IS, quite different from the results of Li et al., who evaluated the characteristics of the corneal topography of patients with KC in a Chinese population \[[@r32]\]. In Li et al.'s study, patients with KC have obvious asymmetry, whereas in the present study, the patients with KC tended to show symmetry. This difference may be due to the different ages at onset, disease duration, disease severity, and inter-observer variability, among other factors \[[@r32]\]. In addition, whether the mutations in *ZNF469* are related to the axial curvature pattern or other topography parameters requires further investigation.

In the present study, the mean CCT of patients with mutations in *ZNF469* was 396 ± 85.9 μm, significantly thinner than in the HM group. CCT is a quantitative human ocular biometric parameter and a hallmark of KC, which has an estimated heritability of up to 95% \[[@r36]\]. Based on the results of genome-wide association studies (GWASs) from different populations (Croatian, Scottish, Indian, Malay, Caucasian, and Latino), Lu et al. performed a meta-analysis for CCT and KC and identified a significant pathogenic locus upstream of *ZNF469* \[[@r18]\]. The combined data across diverse ethnic groups also support a consistent role of *ZNF469* for CCT \[[@r20]\]. The fact that the ZNF469 protein shares 30% homology with the helical parts of three main corneal collagens (COL1A2, COL4A1, and COL1A1) of the human cornea suggests a potential mechanism involving structural contributions \[[@r16]\].

According to Karolak et al. \[[@r4]\], many potentially causative variants related to KC are also found in patients with HM. However, the pathogenesis mechanism of axial HM is completely different from that of KC. Thus, identification of the same variants in patients with axial HM and KC suggests that these variants are not causative for KC. In the present study, we also included an axial HM group. None of the seven mutations identified in the patients with KC were detected in the patients with HM.

The mutation c.3466G\>A coexists with a potentially damaging *DOCK9* mutation in one patient with KC. The patent is male and was diagnosed with bilateral KC at the age of 20 ([Table 3](#t3){ref-type="table"}). Both mutations are predicted to be damaging according to the SIFT score. Thus, the pathogenesis of this patient with KC is more complicated than for the others, and it is difficult to evaluate the effect of the *ZNF469* mutation on this patient with KC.

Only mutations in *ZNF469* identified in the patients with KC were screened in the controls. The negative results indicated only that there is a great chance that these seven mutations in *ZNF469* are harmful nonsynonymous variants and that healthy people would not carry any of them. However, healthy controls may carry other mutations in *ZNF469* that would not cause any ocular abnormality.

To date, the exact etiology of KC is still unclear. The present results suggest a possible role for *ZNF469* in patients with KC in the Chinese population. Wright et al. reported that *ZNF469* may be involved in the transforming growth factor beta (TGFβ) pathway, whose disturbance would lead to the disarray of collagens in human cornea \[[@r33],[@r34]\]. However, it is still too early to definitively resolve whether variants in *ZNF469* are causative for KC. Further analysis of the corneal characteristics of genetic manipulation of *ZNF469* in animal models and corneal materials obtained from keratoplasty surgeries of carriers of mutations in *ZNF469* may help uncover the potential role of *ZNF469* in KC etiology. However, only a few parents or siblings of the identified patients with KC in this study were willing to take genetic tests for mutations in *ZNF469*. Thus, it is difficult to define the genetic pattern of *ZNF469* and trace the origins of the mutations; a pedigree study would help to solve this difficulty. In conclusion, despite some caveats, the present results revealed the enrichment of the mutations in *ZNF469* in patients with sporadic KC from a Han Chinese population for the first time, which indicate alleles in *ZNF469* are potentially important genetic factors contributing to pathogenesis in Chinese patients with KC.
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